Literature DB >> 3193857

Vinpocetine prevents ischemic cell damage in rat hippocampus.

D Sauer1, R Rischke, T Beck, C Rossberg, H D Mennel, G W Bielenberg, J Krieglstein.   

Abstract

The effects of vinpocetine on hippocampal cell damage and local cerebral blood flow (LCBF) were measured in a rat model of forebrain ischemia (2-vessel occlusion and hypotension). Duration of ischemia was 10 min. LCBF was determined after 2 min of recirculation using the 14C-iodoantipyrine technique. Hippocampal cell loss was quantified histologically 7 days post-ischemia. Intraperitoneal application of vinpocetine (10 mg/kg) 15 min prior to ischemia significantly reduced neuronal cell loss in hippocampal CA 1 sector from 60% to 28%. The drug led to a marked increase in blood flow in cortical areas, whereas LCBF remained unchanged in hippocampus and all other structures measured. It is suggested that the protective effect of vinpocetine does not depend on increased postischemic blood flow.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3193857     DOI: 10.1016/0024-3205(88)90485-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

1.  Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation.

Authors:  M Sitges; V Nekrassov
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 2.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

4.  The nootropic drug vinpocetine inhibits veratridine-induced [Ca2+]i increase in rat hippocampal CA1 pyramidal cells.

Authors:  T Zelles; L Franklin; I Koncz; B Lendvai; G Zsilla
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

5.  Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model.

Authors:  Csaba Nyakas; Klára Felszeghy; Róbert Szabó; Jan N Keijser; Paul G M Luiten; Zsolt Szombathelyi; Károly Tihanyi
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

6.  Lack of pharmacokinetic interaction between vinpocetine and oxazepam.

Authors:  G Storm; B Oosterhuis; F A Sollie; H W Visscher; W Sommer; H Beitinger; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

7.  Characterization of phenytoin, carbamazepine, vinpocetine and clorgyline simultaneous effects on sodium channels and catecholamine metabolism in rat striatal nerve endings.

Authors:  María Sitges; Blanca I Aldana; Luz M Chiu; Vladimir Nekrassov
Journal:  Neurochem Res       Date:  2008-08-19       Impact factor: 3.996

Review 8.  Vinpocetine for acute ischaemic stroke.

Authors:  D Bereczki; I Fekete
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 9.  Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

Authors:  Surojit Paul; Eduardo Candelario-Jalil
Journal:  Exp Neurol       Date:  2020-11-02       Impact factor: 5.330

10.  Updates of Recent Vinpocetine Research in Treating Cardiovascular Diseases.

Authors:  Chongyang Zhang; Chen Yan
Journal:  J Cell Immunol       Date:  2020
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.